临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Donepezil HCl
中文名称:盐酸多奈哌齐
CAS号:120011-70-3
分子式: C24H29NO3.HCl 分子量: 416.00
产品形式: Hydrochloride
研发状态: Not yet recruiting
研发用途: Alzheimer Disease
研究机构: Shanghai Synergy Pharmaceutical Sciences Co. Ltd.; Zhejiang Huahai Pharmaceutical Co. Ltd.
研发日期: June 1 2024
研发阶段: Phase 1
Donepezil is a specific and potent AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively.
Cerdulatinib (PRT062070)
中文名称:赛度替尼
CAS号:1198300-79-6
分子式: C20H27N7O3S 分子量: 445.54
产品形式: Free Base
研发状态: Completed
研发用途: Vitiligo
研究机构: Dermavant Sciences GmbH; Dermavant Sciences Inc.
研发日期: September 27 2019
研发阶段: Phase 2
Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively, also inhibits19 other tested kinases with IC50 less than 200 nM.
CBL0137
中文名称:1,1-(9-(2-(异丙基氨基)乙基)-9h-咔唑-3,6-二基)二乙酮
CAS号:1197996-80-7
分子式: C21H24N2O2 分子量: 336.43
产品形式: free base
研发状态: Suspended
研发用途: Locally Advanced or Metastatic Melanoma
研究机构: Fox Chase Cancer Center; Incuron
研发日期: November 30 2022
研发阶段: Early Phase 1
CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.
Tranexamic Acid
中文名称:凝血酸,氨甲环酸
CAS号:1197-18-8
分子式: C8H15NO2 分子量: 157.21
产品形式: free base
研发状态: Recruiting
研发用途: Iatrogenic Endobronchial Bleeding
研究机构: China-Japan Friendship Hospital; The Second Affiliated Hospital of Harbin Medical University; The First Affiliated Hospital of Nanchang University
研发日期: December 1 2023
研发阶段: Early Phase 1
Tranexamic Acid(Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM.
Gedatolisib (PKI-587)
中文名称:吉达利塞
CAS号:1197160-78-3
分子式: C32H41N9O4 分子量: 615.73
产品形式: Free Base
研发状态: Terminated
研发用途: Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome; Acute Myeloid Leukemia in Relapse; de Novo Acute Myeloid Leukemia at Diagnostic
研究机构: Institut Curie; Fondation ARC; National Cancer Institute France
研发日期: August 31 2015
研发阶段: Phase 2
Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM in cell-free assays, respectively. Phase 2.
GDC-0575 (ARRY-575)
中文名称:(R)-N-(4-(3-氨基哌啶-1-基)-5-溴-1H-吡咯并[2,3-B]吡啶-3-基)环丙烷甲酰胺
CAS号:1196541-47-5
分子式: C16H20BrN5O 分子量: 378.27
产品形式: Free Base
研发状态: Completed
研发用途: Lymphoma Solid Tumor
研究机构: Genentech Inc.
研发日期: March 23 2012
研发阶段: Phase 1
GDC-0575 (ARRY-575, RG7741) is a potent and selective CHK1 inhibitor with an IC50 of 1.2 nM.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
